InflaRx (NASDAQ:IFRX) Price Target Raised to $4.00

InflaRx (NASDAQ:IFRX) had its target price hoisted by Cantor Fitzgerald from $2.00 to $4.00 in a research report sent to investors on Monday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

A number of other analysts have also commented on the company. Oppenheimer started coverage on InflaRx in a research note on Friday, April 24th. They set an “outperform” rating and a $5.00 price target on the stock. Wall Street Zen raised InflaRx from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Guggenheim reaffirmed a “buy” rating and issued a $14.00 price objective on shares of InflaRx in a research note on Tuesday, April 21st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of InflaRx in a research note on Friday, March 27th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $7.00.

InflaRx Trading Up 3.7%

IFRX stock opened at $2.52 on Monday. The stock has a market capitalization of $182.17 million, a P/E ratio of -3.55 and a beta of 2.42. InflaRx has a 12 month low of $0.71 and a 12 month high of $2.95. The firm has a 50-day moving average price of $1.32 and a 200-day moving average price of $1.17.

InflaRx (NASDAQ:IFRX) last posted its earnings results on Thursday, May 7th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.08. As a group, equities analysts predict that InflaRx will post -0.55 EPS for the current fiscal year.

Institutional Investors Weigh In On InflaRx

Institutional investors have recently bought and sold shares of the stock. Quadrature Capital Ltd bought a new position in InflaRx in the 4th quarter valued at $104,000. HRT Financial LP bought a new position in shares of InflaRx during the 4th quarter worth $47,000. Insigneo Advisory Services LLC bought a new position in shares of InflaRx during the 4th quarter worth $61,000. Susquehanna International Group LLP bought a new position in shares of InflaRx during the 3rd quarter worth $190,000. Finally, Boothbay Fund Management LLC grew its stake in shares of InflaRx by 10.8% during the 3rd quarter. Boothbay Fund Management LLC now owns 175,114 shares of the company’s stock worth $235,000 after acquiring an additional 17,056 shares during the period. Institutional investors own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V. is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement?1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX?1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro?inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high?unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.